Antibody Bioavailability Protein 
XTalks
AUGUST 8, 2024
Antibody-drug conjugates (ADCs) are at the forefront of targeted cancer therapy. They combine the precision of monoclonal antibodies (mAbs) with the potency of cytotoxic drugs to destroy cancer cells, without harming healthy tissue. For the antibody component, the specificity of tumor cells is paramount. “We
The Pharma Data
APRIL 7, 2023
One of the greatest challenges in modern drug design is to find compounds that satisfy somewhat contradictory requirements – they need to be small enough to permeate human cell membranes, while being large enough to target various protein surfaces and protein–protein interactions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Delveinsight
AUGUST 25, 2020
The drug, Spartalizumab, is an experimental monoclonal antibody designed as immunotherapy to target the human programmed death-1 (PD-1) receptor. The drug is directly delivered to lungs via inhalation to achieve high local exposures, and address the concerns of low oral bioavailability linked to niclosamide. .
Delveinsight
FEBRUARY 16, 2021
Padcev is a first-in-class antibody-drug conjugate (ADC) directed against Nectin-4, a protein. The therapy is the first therapy of its kind to target the Nectin-4 protein. Maribavir is an orally bioavailable anti-CMV compound. located on the surface of cells and highly expressed in bladder cancer.
Roots Analysis
MAY 21, 2024
In fact, it has been observed that around 40% of the pharmaceutical drugs approved by regulatory organizations exhibit poor bioavailability / solubility. Further, every year, poor bioavailability is one of the main causes of drug failure in obtaining approval authorization.
Roots Analysis
MARCH 13, 2022
In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines and gene therapies), by the US FDA, have steadily risen. Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry. Our Social Media Platform.
The Pharma Data
AUGUST 16, 2021
Lebrikizumab is a novel monoclonal antibody (mAb) that binds soluble IL-13 with high affinity, has high bioavailability, a long half-life and blocks IL-13 signaling. “Lebrikizumab is a specific inhibitor of IL-13 that offers robust binding affinity and high bioavailability. 1-4 The U.S. About Lebrikizumab.
Expert insights. Personalized for you.
64 
Let's personalize your content